

Abundant PD-L1 expression in Epstein-Barr Virus-infected

Oncotarget

7, 32925-32932

DOI: [10.18632/oncotarget.9076](https://doi.org/10.18632/oncotarget.9076)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 109.	6.9	217
2	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 853-860.	1.4	13
3	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025
4	Clinical application of early gastric carcinoma with lymphoid stroma based on lymph node metastasis status. <i>Gastric Cancer</i> , 2017, 20, 793-801.	2.7	25
5	Gastric Cancer Genomics: Advances and Future Directions. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 3, 211-217.	2.3	60
6	Novel Targeted Therapies for Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 293-312.	0.6	14
7	Immunophenotypic analysis of tumor infiltrating lymphocytes in Epstein-Barr virus-negative lymphoepithelial carcinoma of the oral cavity: Report of a case. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2017, 29, 581-586.	0.2	3
8	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6002-6011.	3.2	26
9	Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 942-953.	0.6	51
10	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	1.3	33
12	Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. <i>Modern Pathology</i> , 2017, 30, 427-439.	2.9	130
13	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
14	Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760.	2.9	40
15	Molecular testing of gastrointestinal tumours. <i>Diagnostic Histopathology</i> , 2017, 23, 442-449.	0.2	1
16	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Oncolimmunology</i> , 2017, 6, e1356150.	2.1	32
17	Gastric cancer: Basic aspects. <i>Helicobacter</i> , 2017, 22, e12412.	1.6	29
18	Precision medicine in gastric cancer: where are we now?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 193-204.	0.4	0
19	IFN γ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. <i>Scientific Reports</i> , 2017, 7, 17810.	1.6	94

#	ARTICLE	IF	CITATIONS
20	Tumor-infiltrating CD4+ T cells in patients with gastric cancer. <i>Cancer Cell International</i> , 2017, 17, 114.	1.8	30
21	Tissue-Agnostic Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 222-230.	1.8	25
22	The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1606.	1.8	25
23	Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2007-2014.	2.0	50
24	Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	22
25	Elevated Levels of Interferon- γ Are Associated with High Levels of Epstein-Barr Virus Reactivation in Patients with the Intestinal Type of Gastric Cancer. <i>Journal of Immunology Research</i> , 2017, 2017, 1-10.	0.9	15
26	PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0182692.	1.1	200
27	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
28	Immunotherapy for Esophageal and Gastric Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 292-300.	1.8	55
29	The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. <i>Oncotarget</i> , 2017, 8, 38850-38862.	0.8	36
30	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. <i>Oncotarget</i> , 2017, 8, 58887-58902.	0.8	22
31	Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. <i>Gastric Cancer</i> , 2018, 21, 925-935.	2.7	13
32	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018, 3, e000326.	2.0	52
33	Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. <i>Cancer Science</i> , 2018, 109, 272-278.	1.7	42
34	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
35	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <i>Seminars in Cancer Biology</i> , 2018, 52, 241-252.	4.3	12
36	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 316-320.	3.0	171
37	The Basics of Cancer Immunotherapy. , 2018, , .		5

#	ARTICLE	IF	CITATIONS
38	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
39	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. <i>OncImmunology</i> , 2018, 7, e1356144.	2.1	113
40	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 20.	6.9	32
41	Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies. <i>Oncology Research and Treatment</i> , 2018, 41, 266-271.	0.8	30
42	Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. <i>Oncology Research and Treatment</i> , 2018, 41, 272-280.	0.8	35
43	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	7.7	396
44	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
45	Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 829-839.	0.8	57
46	CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 643-651.	1.4	12
47	Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. <i>Pathobiology</i> , 2018, 85, 50-63.	1.9	101
48	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	1.1	55
49	The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. <i>Neuropathology</i> , 2018, 38, 125-134.	0.7	25
50	The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. <i>Annals of Surgery</i> , 2018, 268, 992-999.	2.1	77
51	Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. <i>Future Virology</i> , 2018, 13, 803-818.	0.9	3
52	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 221-227.	0.8	6
53	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 280-291.	1.8	4
54	Single agent anti PD-1 inhibitors in esophageal cancer—a first step in a new therapeutic direction. <i>Journal of Thoracic Disease</i> , 2018, 10, 1308-1313.	0.6	7
55	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118

#	ARTICLE	IF	CITATIONS
56	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8239-8250.	1.0	32
57	New therapeutic options opened by the molecular classification of gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 1942-1961.	1.4	33
58	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 167-174.	1.0	0
59	Emerging Therapies in the Management of Advanced-Stage Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 404.	1.6	24
60	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. <i>Scientific Reports</i> , 2018, 8, 13887.	1.6	10
61	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 196-207.	0.6	18
62	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
63	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
64	EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes. <i>Cancers</i> , 2018, 10, 102.	1.7	51
65	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 374.	2.2	51
66	Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer. <i>Cancers</i> , 2018, 10, 167.	1.7	63
67	The Microenvironment in Epstein-Barr Virus-Associated Malignancies. <i>Pathogens</i> , 2018, 7, 40.	1.2	40
68	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	15.2	1,071
69	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2079.	1.8	26
70	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
71	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	3.4	78
72	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
73	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018, 21, 1064-1070.	2.7	25

#	ARTICLE	IF	CITATIONS
74	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. <i>Gastric Cancer</i> , 2019, 22, 77-90.	2.7	41
75	Epstein-Barr Virus and Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 29-53.	9.6	303
76	Long-term survival with stable disease after multidisciplinary treatment for synchronous liver metastases from gastric cancer: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 65, 317-321.	0.2	0
77	Gastric Cancer in the Era of Immune Checkpoint Blockade. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	23
78	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
79	Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. <i>Cancer Medicine</i> , 2019, 8, 6114-6126.	1.3	82
80	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.	3.2	142
81	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019, 4, e000470.	2.0	35
82	Clinicopathologic Characteristics of Epstein-Barr Virus-Associated Gastric Cancer Over the Past Decade in Japan. <i>Microorganisms</i> , 2019, 7, 305.	1.6	23
83	Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. <i>PLoS ONE</i> , 2019, 14, e0211358.	1.1	31
84	Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 351-352.	0.6	3
85	Assessing the interactions between radiotherapy and antitumour immunity. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 729-745.	12.5	183
86	Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2019, 421, 319-359.	0.7	29
87	Molecular Mechanisms of Inflammation: Induction, Resolution and Escape by <i>Helicobacter pylori</i> . <i>Current Topics in Microbiology and Immunology</i> , 2019, , .	0.7	5
88	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
89	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
90	Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2106.	1.8	145
91	iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. <i>Nature Communications</i> , 2019, 10, 1336.	5.8	73

#	ARTICLE	IF	CITATIONS
92	Clinicopathological, immune and molecular correlates of <i>PD-L2</i> methylation in gastric adenocarcinomas. <i>Epigenomics</i> , 2019, 11, 639-653.	1.0	17
93	Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. <i>Frontiers in Oncology</i> , 2019, 9, 136.	1.3	36
94	Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders. <i>Frontiers in Oncology</i> , 2019, 9, 127.	1.3	31
95	PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. <i>Oncolmmunology</i> , 2019, 8, e1544442.	2.1	51
96	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1656-1672.	7.7	37
97	Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1328-1333.	0.8	22
98	Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. <i>American Journal of Surgical Pathology</i> , 2019, 43, 851-860.	2.1	47
99	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
100	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
101	Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?. <i>Annals of Oncology</i> , 2019, 30, 159-161.	0.6	6
102	Genomic Applications in Pancreatic and Gastric Tumors. , 2019, , 401-418.		0
103	Rationale for Immunotherapy in Gastrointestinal Malignancies. , 2019, , 287-297.		1
104	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. <i>Gastric Cancer</i> , 2019, 22, 486-496.	2.7	72
105	Molecular profiling in gastroesophageal cancer—clinical routine and future perspective. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 440-444.	0.3	3
106	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	3.4	19
107	Thirty years of Epstein-Barr virus-associated gastric carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 353-365.	1.4	41
109	Clinical impact of Epstein-Barr virus status on the incidence of lymph node metastasis in early gastric cancer. <i>Digestive Endoscopy</i> , 2020, 32, 316-322.	1.3	16
110	Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 587460.	2.2	87

#	ARTICLE	IF	CITATIONS
111	Tackling diversity within diversity. <i>Annals of Oncology</i> , 2020, 31, 970-972.	0.6	1
112	Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?. <i>Frontiers in Oncology</i> , 2020, 10, 912.	1.3	6
113	Towards Personalization in the Curative Treatment of Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614907.	1.3	10
114	Role of Immunotherapy in Advanced Gastroesophageal Cancer. <i>Current Oncology Reports</i> , 2020, 22, 112.	1.8	5
115	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , 2020, 126, 4788-4799.	2.0	14
116	The Crosstalk between Microbiome and Immune Response in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6586.	1.8	49
117	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168.	1.7	13
118	Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 1011-1020.	0.6	95
119	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link with Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1427.	1.0	55
120	The roles of programmed death ligand 1 in virus-associated cancers. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104368.	1.0	16
121	Current status of immune checkpoint inhibitors for gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 565-578.	2.7	133
122	Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. <i>Cancer Treatment Reviews</i> , 2020, 88, 102030.	3.4	44
123	Epstein-Barr virus-associated gastric cancer: disease that requires special approach. <i>Gastric Cancer</i> , 2020, 23, 951-960.	2.7	26
124	Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. <i>Journal of Leukocyte Biology</i> , 2020, 108, 633-646.	1.5	26
125	Gastric cancer: genome damaged by bugs. <i>Oncogene</i> , 2020, 39, 3427-3442.	2.6	37
126	Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters. <i>Journal of Clinical Medicine</i> , 2020, 9, 1966.	1.0	10
127	Young-onset gastric cancer and Epstein-Barr Virus (EBV) – a major player in the pathogenesis?. <i>BMC Cancer</i> , 2020, 20, 34.	1.1	22
128	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. <i>Cancers</i> , 2020, 12, 301.	1.7	7

#	ARTICLE	IF	CITATIONS
129	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394.		39
130	Select Epstein-Barr Virus-Associated Digestive Tract Lesions for the Practicing Pathologist. Archives of Pathology and Laboratory Medicine, 2021, 145, 562-570.	1.2	4
131	A study of the immune infiltrate and patient outcomes in esophageal cancer. Carcinogenesis, 2021, 42, 395-404.	1.3	15
132	Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab. Targeted Oncology, 2021, 16, 237-248.	1.7	7
133	Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article. Oncology Research and Treatment, 2021, 44, 485-494.	0.8	12
134	Current treatment and recent progress in gastric cancer. Ca-A Cancer Journal for Clinicians, 2021, 71, 264-279.	157.7	759
135	Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open, 2021, 6, 100036.	2.0	87
136	Recent advances in immune therapies for gastric cancer. Cancer Gene Therapy, 2021, 28, 924-934.	2.2	16
137	Brazilian Group of Gastrointestinal Tumours™ consensus guidelines for the management of oesophageal cancer. Ecanermedicalscience, 2021, 15, 1195.	0.6	1
138	Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteria. Journal of Pathology: Clinical Research, 2021, 7, 397-409.	1.3	4
139	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318.	1.4	7
140	Microsatellite instability in Gastric Cancer: Between lights and shadows. Cancer Treatment Reviews, 2021, 95, 102175.	3.4	88
141	The tumour immune microenvironment in oesophageal cancer. British Journal of Cancer, 2021, 125, 479-494.	2.9	17
142	Epstein-Barr Virus-Associated Gastric Cancer: Old Entity with New Relevance. , 0, , .		1
143	Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Future Oncology, 2021, 17, 1553-1569.	1.1	9
144	Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers, 2021, 13, 1715.	1.7	19
145	Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma. Cancers, 2021, 13, 2717.	1.7	21
146	Optimized PD-L1 scoring of gastric cancer. Gastric Cancer, 2021, 24, 1115-1122.	2.7	25

#	ARTICLE	IF	CITATIONS
147	Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer. PeerJ, 2021, 9, e11481.	0.9	13
148	Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy. Journal of Surgical Research, 2021, 261, 130-138.	0.8	7
149	The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine, 2021, 10, 2108.	1.0	20
150	A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. Translational Cancer Research, 2021, 10, 2586-2595.	0.4	1
151	The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment. Histopathology, 2021, 79, 451-464.	1.6	5
152	A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. Gastric Cancer, 2021, 24, 1227-1241.	2.7	21
153	Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer. Scientific Reports, 2021, 11, 12264.	1.6	13
154	Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 664032.	1.3	7
155	Pathomorphological and molecular genetic features of diffuse gastric cancer. Bulletin of Siberian Medicine, 2021, 20, 168-175.	0.1	0
156	Comparing immunotherapies to other frequently used treatments of gastric cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1221-1232.	1.3	2
157	Research status on immunotherapy trials of gastric cancer. World Journal of Clinical Cases, 2021, 9, 5782-5793.	0.3	5
158	New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond. Expert Review of Hematology, 2021, 14, 741-750.	1.0	0
159	MicroRNA and Other Non-Coding RNAs in Epstein-Barr Virus-Associated Cancers. Cancers, 2021, 13, 3909.	1.7	15
160	Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications. Frontiers in Immunology, 2021, 12, 705999.	2.2	24
161	Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. Annals of Translational Medicine, 2021, 9, 1489-1489.	0.7	5
162	<i>HNRNPL</i> Is Identified and Validated as a Prognostic Biomarker Associated with Microsatellite Instability in Human Gastric Cancer. DNA and Cell Biology, 2021, 40, 1251-1260.	0.9	2
163	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Current Treatment Options in Oncology, 2021, 22, 100.	1.3	11
164	Genome instability and success of checkpoint inhibitors: form and levels matter. Annals of Oncology, 2021, 32, 1073-1074.	0.6	2

#	ARTICLE	IF	CITATIONS
165	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 939-944.	1.4	3
166	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1
167	Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology, 2021, 78, 148-161.	1.6	17
168	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 2019, 4, .	2.3	345
169	Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients.. Journal of Clinical Oncology, 2017, 35, 50-50.	0.8	1
170	PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. World Journal of Meta-analysis, 2019, 7, 101-109.	0.1	7
171	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Oncotarget, 2016, 7, 72099-72112.	0.8	16
172	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget, 2017, 8, 13320-13328.	0.8	60
173	Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget, 2017, 8, 26356-26367.	0.8	54
174	Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget, 2017, 8, 82399-82414.	0.8	19
175	Biomarkers for gastric cancer: molecular classification revisited. Precision and Future Medicine, 2017, 1, 59-68.	0.5	25
176	Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer. Precision and Future Medicine, 2019, 3, 165-175.	0.5	4
177	EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives. Frontiers in Oncology, 2020, 10, 583463.	1.3	70
178	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697.	1.4	23
179	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World Journal of Gastroenterology, 2019, 25, 5773-5788.	1.4	69
180	Significant function and research progress of biomarkers in gastric cancer (Review). Oncology Letters, 2020, 19, 17-29.	0.8	26
181	Tumor immune response and immunotherapy in gastric cancer. Journal of Pathology and Translational Medicine, 2020, 54, 20-33.	0.4	59
182	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	0.8	46

#	ARTICLE	IF	CITATIONS
183	Identification and Validation of a Malignant Cell Subset Marker-Based Polygenic Risk Score in Stomach Adenocarcinoma Through Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 720649.	1.8	7
184	News in systemic treatment of advanced and metastatic carcinoma of the stomach. <i>Klinicka Farmakologie A Farmacie</i> , 2018, 32, 15-18.	0.1	0
185	Immunotherapy in Esophageal Cancer. , 2020, , 289-310.		0
186	Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.5	3
187	Novel Immunotherapeutic Approach in Gastric Cancer. <i>Acta Medica Bulgarica</i> , 2020, 47, 47-54.	0.0	1
188	Monoclonal Antibody Therapy Against Gastrointestinal Tract Cancers. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 97-111.	0.2	0
189	Molecular portrait of stomach cancer associated with the Epstein-Barr virus. <i>Uspehi Molekularnoj Onkologii</i> , 2020, 7, 27-36.	0.1	0
190	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. <i>Ecancelmedicalsecience</i> , 2020, 14, 1126.	0.6	3
191	Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. <i>Biomolecules</i> , 2021, 11, 1792.	1.8	4
192	Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 752023.	1.8	14
193	Brazilian Group of Gastrointestinal Tumours™ consensus guidelines for the management of gastric cancer. <i>Ecancelmedicalsecience</i> , 2020, 14, 1126.	0.6	3
194	Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma. <i>Cancers</i> , 2022, 14, 586.	1.7	2
195	Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 759652.	1.3	3
196	Immunotherapy for Gastroesophageal Tumors: Is There Still Hope for Efficacy?. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
197	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
198	Gastric Carcinoma with Lymphoid Stroma: A Combination of Mismatch Repair Deficient Medullary Type and Epstein-Barr Virus-associated Gastric Carcinomas. <i>International Journal of Surgical Pathology</i> , 2022, 30, 623-633.	0.4	3
199	Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. <i>Cancer Biology and Therapy</i> , 2022, 23, 191-200.	1.5	10
200	Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma. <i>Oncology Research and Treatment</i> , 2022, 45, 375-379.	0.8	5

#	ARTICLE	IF	CITATIONS
201	Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers. <i>Cancers</i> , 2022, 14, 1736.	1.7	4
202	Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. , 2022, 10, e004080.		33
203	PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis. <i>Discover Oncology</i> , 2022, 13, 19.	0.8	14
204	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
205	Epstein-Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 734293.	2.2	24
206	Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients. <i>Frontiers in Immunology</i> , 2022, 13, 783695.	2.2	5
207	Target Therapy and Immunotherapy For Gastric Cancer - Recent Updates. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	1
208	Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. <i>Frontiers in Immunology</i> , 2022, 13, 810539.	2.2	4
214	Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers. <i>Gut and Liver</i> , 2022, , .	1.4	6
215	The current management and biomarkers of immunotherapy in advanced gastric cancer. <i>Medicine (United States)</i> , 2022, 101, e29304.	0.4	16
216	Viral Infection in Esophageal, Gastric, and Colorectal Cancer. <i>Healthcare (Switzerland)</i> , 2022, 10, 1626.	1.0	2
217	Gastric cancer with Epstein-Barr virus heterogeneity: Evaluation of the frequency, clinicopathologic features, and genomic profiles. <i>Pathology Research and Practice</i> , 2022, 238, 154108.	1.0	4
218	Therapeutic approaches to Epstein-Barr virus cancers. <i>Current Opinion in Virology</i> , 2022, 56, 101260.	2.6	7
219	Research Progress of Serology and Tumor Markers in the Diagnosis of Early Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 7784-7790.	0.0	0
220	Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4670.	1.7	4
221	Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. , 2022, , 1-25.		0
222	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
223	PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. <i>Pathologica</i> , 2022, 114, 352-364.	1.3	13

#	ARTICLE	IF	CITATIONS
224	Characterization of pyruvate metabolism and citric acid cycle patterns predicts response to immunotherapeutic and ferroptosis in gastric cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	8
225	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
226	Medullary carcinoma of the ampulla has distinct clinicopathologic characteristics including common association with microsatellite instability and PD-L1 expression. <i>Human Pathology</i> , 2023, 131, 38-46.	1.1	2
227	Descriptive Study of Tumor Immune Microenvironment and Epstein-Barr Virus Infection in Gastric Adenocarcinoma. <i>Acta Gastroenterologica Latinoamericana</i> , 2022, 52, 484-493.	0.0	0
228	Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion. <i>Viruses</i> , 2023, 15, 176.	1.5	4
230	Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
232	Assessing Epstein-Barr virus in gastric cancer: clinicopathological features and prognostic implications. <i>Infectious Agents and Cancer</i> , 2023, 18, .	1.2	1
233	New Advances in Molecular Typing of Gastric Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 2392-2396.	0.0	0
234	Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. <i>Cancer Management and Research</i> , 0, Volume 15, 265-275.	0.9	0
235	Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer. <i>Molecular Biology</i> , 2023, 57, 61-73.	0.4	1
236	Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report. <i>Medicine (United States)</i> , 2023, 102, e33377.	0.4	3
246	PACS: Prediction and analysis of cancer subtypes from multi-omics data based on a multi-head attention mechanism model. , 2023, , .		0